Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	4.07M 0 3.57M 3.29M 3.08M 5.78M 384M 5.9M 39.55M 15.31M 190M 15.29M 14.96M 658M	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	4.07M 0 3.57M 3.29M 3.08M 5.78M 384M 5.9M 39.55M 15.31M 190M 15.29M 14.96M 658M	EV / Sales 2026 *	2.74x	EV / Sales 2027 *	1.57x
Free-Float	82.9%	Yield 2026 *	-	Yield 2027 *	-

06-24	Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization	CI
06-02	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI
05-20	Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Evogene Ltd., Q1 2026 Earnings Call, May 20, 2026
05-20	Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing	RE
05-18	Evogene Ltd.'S Subsidiary Ag Plenus Ltd. and Bayer Ag to Discontinue Their Herbicide Development Project	CI
04-24	Evogene's Casterra unit eyes castor crop growth in Brazil	RE
04-03	Evogene reports receipt of Nasdaq minimum bid price notification	RE
04-02	Evogene Gets Nasdaq Minimum Bid Price Notification	MT
03-05	Evogene Ltd., Q4 2025 Earnings Call, Mar 05, 2026
03-05	Evogene Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-25	Evogene substantially completed divestment of non-core subsidiaries	RE
02-17	Evogene Ltd. and Queensland University of Technology Announce A Collaboration to Advance AI-Driven Cancer Therapeutics	CI

02/10/23	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
18/08/23	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
29/07/21	EVOGENE : Aegis Capital Starts Evogene at Buy	MT
01/12/20	EVOGENE : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

06-02	Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica	PR
05-20	Evogene : Q1 2026 Consolidated Financial Statements	PU
05-20	Evogene: Q1 Earnings Snapshot	AQ
05-20	Evogene Reports First Quarter 2026 Financial Results	PR
05-12	Evogene to Present at the 24th Schrödinger European User Group Meeting	PR

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	01/12/2004
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	01/01/2022

Evogene Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd

Latest news : Evogene Ltd

Last Transcript: Evogene Ltd

Analysts' recommendations: Evogene Ltd

Press Releases: Evogene Ltd

News in other languages: Evogene Ltd

Quotes and Performance

Managers and Directors: Evogene Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	03/06/2010
Sarit Firon CHM	Chairman	60	01/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD	-0.43%	-5.52%	-	-	4.07M
LONZA GROUP AG	-0.48%	+7.20%	-5.65%	+1.02%	46.2B
REVOLUTION MEDICINES, INC.	+2.19%	+11.71%	+393.31%	+580.42%	38.71B
IQVIA HOLDINGS INC.	+2.53%	+13.93%	+21.38%	-12.81%	31.9B
BEONE MEDICINES AG	+1.65%	+3.61%	+16.04%	+55.62%	31.12B
CELLTRION, INC.	-4.16%	-2.58%	+8.94%	+26.14%	23.77B
ASCENDIS PHARMA A/S	-0.32%	+12.96%	-	-	16.2B
MEDPACE HOLDINGS, INC.	+1.37%	+14.53%	+69.64%	+130.07%	15.05B
EUROFINS SCIENTIFIC SE	+1.00%	+10.30%	+13.31%	+20.31%	13.74B
IONIS PHARMACEUTICALS, INC.	+3.63%	+9.53%	+103.97%	+98.73%	13.42B
Average	+0.70%	+9.14%	+77.62%	+112.44%	25.57B
Weighted average by Cap.	+0.75%	+8.71%	+88.75%	+130.99%

	2026 *	2027 *
Net sales	1.48M 0 1.3M 1.2M 1.12M 2.11M 140M 2.15M 14.42M 5.58M 69.19M 5.57M 5.45M 240M	2.6M 0 2.28M 2.1M 1.97M 3.69M 245M 3.77M 25.26M 9.77M 121M 9.76M 9.55M 420M
Net income	-16.69M -0 -14.63M -13.49M -12.63M -23.68M -1.57B -24.17M -162M -62.72M -778M -62.66M -61.29M -2.7B	-13.92M -0 -12.2M -11.25M -10.53M -19.74M -1.31B -20.15M -135M -52.3M -649M -52.25M -51.11M -2.25B
Net Debt	-	-